STOCK ICONS DRUG DISCOVERY FULL
STOCK ICONS DRUG DISCOVERY SOFTWARE
STOCK ICONS DRUG DISCOVERY TRIAL

Examples include target discovery and validation using knowledge graphs and small-molecule design using generative neural networks. These firms use data and analytics to improve one or more specific use cases at various points in the value chain.

STOCK ICONS DRUG DISCOVERY SOFTWARE

Much of the historical progress has been led by AI-native drug discovery companies that offer software or a service to pharma players. They can look to the AI-first drug discovery startups that are leading the way for lessons and a roadmap for the journey ahead. To take advantage, companies must make investments in data, technology, and new skills and behaviors throughout the R&D organization.

STOCK ICONS DRUG DISCOVERY FULL

Instead, achieving full value from AI requires a transformation of the discovery process. From our experience with many companies, this is rarely the case. It may be tempting to think that AI can be delivered through a new tool or a single team. In practice, this means spending the time needed to understand the full impact that AI is having on R&D, which includes separating hype from actual achievement and recognizing the difference between individual software solutions and end-to-end AI-enabled drug discovery. New players are scaling up fast and creating significant value, but the applications are diverse and pharma companies need to determine where and how AI can most add value for them. Given the transformative potential of AI, pharma companies need to plan for a future in which AI is routinely used in drug discovery.

This AI-fueled pipeline has been expanding at an annual rate of almost 40%. We recently published an analysis that showed that biotech companies using an AI-first approach have more than 150 small-molecule drugs in discovery and more than 15 already in clinical trials.

Technology, Media, and Telecommunicationsĭelivering on the promise requires action on five strategic and operational tracks.Īrtificial intelligence has been making inroads in drug discovery for a good part of the last decade.

This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. Technavio is a leading global technology research and advisory company.

STOCK ICONS DRUG DISCOVERY TRIAL

Technavio's in-depth research has direct and indirect COVID-19 impacted market research reports.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Charles River Laboratories International Inc.ROW - Market size and forecast 2020-2025.Asia - Market size and forecast 2020-2025.Europe - Market size and forecast 2020-2025.North America - Market size and forecast 2020-2025.

Stock icons drug discovery